Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603–608

Article  PubMed  Google Scholar 

Carvalho S, Raposo AC, Martins FB, Grosso AR, Sridhara SC, Rino J, Carmo-Fonseca M, de Almeida SF (2013) Histone methyltransferase SETD2 coordinates FACT recruitment with nucleosome dynamics during transcription. Nucleic Acids Res 41:2881–2893

Article  CAS  PubMed  Google Scholar 

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404

Article  PubMed  Google Scholar 

Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M et al (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463–469

Article  CAS  PubMed  Google Scholar 

Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, Silva TC, Groeneveld C, Wong CK, Cho SW et al (2018) The chromatin accessibility landscape of primary human cancers. Science 362:eaav1898

Article  PubMed  Google Scholar 

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744

Article  CAS  PubMed  Google Scholar 

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508

Article  CAS  PubMed  Google Scholar 

Heo Y, Kim WJ, Cho YJ, Jung JW, Kim NS, Choi IY (2025) Advances in cancer genomics and precision oncology. Genes Genom 47:399–416

Article  Google Scholar 

Hu L, Lin J, Sun L, Berezuk AM, Tuttle KS, Zhu X, Seo HS, Dhe-Paganon S, Li P, Sun Y et al (2026) Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells. Nat Chem Biol. https://doi.org/10.1038/s41589-025-02131-8

Article  PubMed  Google Scholar 

Lee EB, Yun HJ, Park SH, Ko EH, Jung YJ, Liu R, Park YY, Lee JH (2025) Targeting phosphofructokinase 2 the isoform PFKFB4 suppresses glioblastoma proliferation and malignancy. Genes Genomics 47:1319–1331

Article  CAS  PubMed  Google Scholar 

Li J, Duns G, Westers H, Sijmons R, van den Berg A, Kok K (2016) SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget 7:50719–50734

Article  PubMed  Google Scholar 

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P (2015) The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst 1:417–425

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820

Article  PubMed  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251

Article  CAS  PubMed  Google Scholar 

Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478

Article  CAS  PubMed  Google Scholar 

Morgan MA, Shilatifard A (2015) Chromatin signatures of cancer. Genes Dev 29:238–249

Article  CAS  PubMed  Google Scholar 

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

Article  CAS  PubMed  Google Scholar 

Reuss DE (2023) Updates on the WHO diagnosis of IDH-mutant glioma. J Neurooncol 162:461–469

Article  PubMed  Google Scholar 

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47

Article  PubMed  PubMed Central  Google Scholar 

Ryan MB, Der CJ, Wang-Gillam A, Cox AD (2015) Targeting RAS-mutant cancers: is ERK the key? Trends Cancer 1:183–198

Article  PubMed  Google Scholar 

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154

Article  CAS  PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

Article  CAS  PubMed  Google Scholar 

Terekhanova NV, Karpova A, Liang WW, Strzalkowski A, Chen S, Li Y, Southard-Smith AN, Iglesia MD, Wendl MC, Jayasinghe RG et al (2023) Epigenetic regulation during cancer transitions across 11 tumour types. Nature 623:432–441

Article  CAS  PubMed  Google Scholar 

Tesileanu CMS, Vallentgoed WR, Sanson M, Taal W, Clement PM, Wick W, Brandes AA, Baurain JF, Chinot OL, Wheeler H et al (2021) Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol 141:945–957

Article  CAS  PubMed  Google Scholar 

Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–483

Article  CAS  PubMed  Google Scholar 

Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE et al. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234

Wen PY, Packer RJ (2021) The 2021 WHO classification of tumors of the central nervous system: clinical implications. Neuro Oncol 23:1215–1217

Article  PubMed  Google Scholar 

Xie Y, Sahin M, Sinha S, Wang Y, Nargund AM, Lyu Y, Han S, Dong Y, Hsieh JJ, Leslie CS et al (2022) SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat Cancer 3:188–202

Article  CAS  PubMed  Google Scholar 

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30

Article  CAS  PubMed  Google Scholar 

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773

Article  CAS  PubMed  Google Scholar 

Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284–287

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Fang Y, Tang Y, Han S, Jia J, Wan X, Chen J, Yuan Y, Zhao B, Fang D (2022) SMYD5 catalyzes histone H3 lysine 36 trimethylation at promoters. Nat Commun 13:3190

Article  PubMed  Google Scholar